No connection

Search Results

AKAN vs IMCC

AKAN
Akanda Corp.
BEARISH
Price
$0.82
Market Cap
$1.7M
Sector
Healthcare
AI Confidence
95%
IMCC
IM Cannabis Corp.
BEARISH
Price
$0.36
Market Cap
$2.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AKAN
0.01
IMCC
--
Forward P/E
AKAN
--
IMCC
-0.28
P/B Ratio
AKAN
0.04
IMCC
-0.8
P/S Ratio
AKAN
2.06
IMCC
0.04
EV/EBITDA
AKAN
0.55
IMCC
-3.49

Profitability

Gross Margin
AKAN
24.91%
IMCC
17.7%
Operating Margin
AKAN
-443.84%
IMCC
-31.42%
Profit Margin
AKAN
-266.31%
IMCC
-20.68%
ROE
AKAN
-60.86%
IMCC
--
ROA
AKAN
-28.69%
IMCC
-10.92%

Growth

Revenue Growth
AKAN
--
IMCC
17.6%
Earnings Growth
AKAN
--
IMCC
--

Financial Health

Debt/Equity
AKAN
0.12
IMCC
--
Current Ratio
AKAN
1.25
IMCC
0.67
Quick Ratio
AKAN
0.89
IMCC
0.41

Dividends

Dividend Yield
AKAN
--
IMCC
--
Payout Ratio
AKAN
0.0%
IMCC
0.0%

AI Verdict

AKAN BEARISH

AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.

Strengths
Graham Number suggests a defensive fair value of $281.01
Low Price/Book ratio (0.04) indicates potential undervaluation on asset basis
Debt/Equity ratio of 0.12 suggests conservative capital structure
Risks
Piotroski F-Score of 3/9 signals weak financial health and operational inefficiency
Negative profit, operating, and return metrics across the board (ROE: -60.86%, ROA: -28.69%)
No revenue or earnings growth data available, suggesting stagnation or collapse
IMCC BEARISH

IMCC exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 and the absence of a Graham Number or Altman Z-Score due to negative equity (Price/Book: -0.80). While the company has shown recent revenue growth of 17.6% and a series of EPS 'beats,' these are marginal improvements on a foundation of deep losses and negative margins. The catastrophic 5-year price decline of 99.9% and a current ratio of 0.67 indicate a high risk of insolvency and a lack of investor confidence.

Strengths
Positive YoY revenue growth of 17.60%
Recent quarterly EPS beats (3 of last 4 quarters)
Extremely low Price/Sales ratio (0.04)
Risks
Negative equity as indicated by Price/Book of -0.80
Severe liquidity risk with a Current Ratio of 0.67 and Quick Ratio of 0.41
Persistent negative operating margins (-31.42%)

Compare Another Pair

AKAN vs IMCC: Head-to-Head Comparison

This page compares Akanda Corp. (AKAN) and IM Cannabis Corp. (IMCC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile